Nucleic Acid Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: February 23, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 3.9 billion |
|
Revenue Forecast in 2030 |
US$ 10.43 billion |
|
CAGR |
11.55% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Product, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global nucleic acid therapeutics market was valued at US$ 3.9 billion in 2021 and is expected to register a revenue CAGR of 11.55% to reach US$ 10.43 billion by 2030.
Nucleic Acid Therapeutics Market Fundamentals
Nucleic acid-based therapeutics are medications based on nucleic acid, mainly DNA and RNA. It is a new class of therapeutics treating unmet medical needs. These drugs are capable of targeting disease at the molecular level by preventing disease expression-causing proteins. Cancer, viral infections, and genetic disorders are mostly treated with nucleic acid-based therapeutics.
Nucleic acid-based techniques target gene expression by altering the DNA or RNA. They significantly reduce the synthesis of certain defective proteins while leaving the other proteins unaffected. In contrast to traditional treatments, which provide ephemeral therapeutic benefits, these therapies produce specific, long-lasting, and sometimes permanent cures for an underlying medical condition. The fundamental mechanism of action for various nucleic acid therapeutics is based on complementary base pairing with endogenous DNA or RNA. Intrathecal, subcutaneous, or intravenous routes administer nucleic acid therapeutics. There is a potential for producing an intranasal version of these authorized nucleic acid-based therapeutics.
[65756756]
Nucleic Acid Therapeutics Market Dynamics
The association of nucleic acids with multiple chronic diseases and their therapeutic ability proved to be an effective treatment method for many pulmonary diseases, such as asthma, COPD, and lung cancer. The therapeutic effectiveness has been effectively demonstrated in several studies over the past few decades. The unique structures of the lungs allow for nucleic acid administration via intravenous and pulmonary routes. Inhalation and intranasal methods have been determined to be the most effective delivery method for nucleic acid-based drugs. Researchers have changed the molecular structure of nucleic acids for optimum therapeutic application to boost their resistance to nuclease breakdown and minimize immunological reactions.
High investment by top players in nucleic acid therapeutics is supporting the revenue growth of the global nucleic acid therapeutics market. For instance, On January 9, 2022, Agilent Technologies announced a US$ 725 million investment in nucleic acid-based therapies. Medicinal nucleic acids, commonly known as therapeutic oligonucleotides or oligos, are small DNA and RNA molecules used as active pharmaceutical ingredients (API) in a variety of medications. The investment is expected to be used to double API production capacity.
The presence of many nucleic acid therapeutics in the pipeline is expected to support the nucleic acid therapeutics market during the forecast period. For instance, Orna Therapeutics is developing a treatment for difficult conditions when conventional treatment techniques have failed. Orna believes its oRNATM technology may be used to solve current immunotherapies’ limitations by delivering chimeric antigen receptors (CARs) directly to patients’ immune cells within the body (isCARTM therapy). Orna’s oRNATM technology has far-reaching potential applications, with a diverse pipeline of cancer, genetic illness, and infectious disease targets.
However, the high cost of products and stringent regulations are the most prominent restraints in the global nucleic acid therapeutics market.
Nucleic Acid Therapeutics Market Ecosystem
The global nucleic acid therapeutics market has been analyzed from four perspectives: product, application, end user, and region.
Nucleic Acid Therapeutics Market by Product
[76575352]
Based on the product, the global nucleic acid therapeutics market has been segmented into RNA interference (RNAi) and short interfering RNAs (siRNA) and anti-sense oligonucleotides and DNA aptamers.
The RNA interference (RNAi) and short interfering RNAs (siRNA) segment is dominant in the global nucleic acid therapeutics market. RNA interference (RNAi) and short-interfering RNAs (siRNA) are two of the most powerful tools in nucleic acid therapeutics. RNAi and siRNA offer several advantages to scientists and medical professionals looking to develop treatments for a variety of diseases. RNAi works by targeting specific mRNA sequences and blocking the translation of the mRNA into proteins. This process allows scientists to selectively silence genes, either permanently or temporarily. This process can let researchers understand how genes work and how they can be manipulated to treat diseases. On the other hand, siRNA works by targeting specific mRNA sequences and blocking the translation of the mRNA into proteins. This process can allow scientists to control specific gene expressions and provides scientists with a powerful tool to alter disease processes.
Nucleic Acid Therapeutics Market by Application
Based on application, the global nucleic acid therapeutics market has been segmented into multigenetic disorders and monogenetic disorders.
The monogenetic disorder segment accounts for the majority of the market revenue share. Treatments with nucleic acid therapeutics can alter genes through editing, addition, replacement, or inhibition to provide long-lasting or even curative effects. Nucleic acid therapeutics are becoming progressively more popular in the medical field as a way to treat monogenetic disorders, which are caused by a mutation in a single gene. With nucleic acid therapeutics, physicians can replace the mutated gene with a healthy gene that can produce a normal protein. Since only the mutated gene is replaced, there is no risk of side effects from drugs or radiation that may occur with other treatments. Furthermore, this type of therapy is much less expensive than traditional treatments, and can be customized.
Nucleic Acid Therapeutics Market by End User
Based on end user, the global nucleic acid therapeutics market has been segmented into hospitals & clinics and academic & research institutes.
The hospitals & clinics segment dominates the global nucleic acid therapeutics market. The rise in the number of patients relying on hospitals and clinics for treatment is the key factor supporting the segment’s revenue growth. Additionally, frequent visits by patients with chronic diseases for monitoring the disease are also expected to support segment revenue growth.
Nucleic Acid Therapeutics Market by Region
Based on region, the global nucleic acid therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates the global market. Many market players in this region are manufacturing nucleic acid therapeutics for rare diseases. For instance, Merck & Co. declared in August 2022 that it had teamed up with Orna Therapeutics to create a new class of therapeutic RNA. This partnership discovered and commercialized innovative RNA-based medicines for oncology, infectious disease, and vaccine development. Moreover, increased per capita income, enhanced healthcare infrastructure, and regionally modified reimbursement practices are propelling regional market revenue growth.
The nucleic acid therapeutics market in Europe is characterized by the launch of numerous new projects based on nucleic acid-based therapeutics. For instance, according to pharmaceutical technology, 17.6% of all projects announced on nucleic acid therapies in 2021 were in Western Europe, making it a highly attractive region for FDI projects.
In the upcoming years, the Asia Pacific nucleic acid therapeutics market is anticipated to expand significantly, primarily due to factors such as, the rising incidence of chronic diseases, genetic disorders, infectious diseases, and the rise in funding from public and private institutions. The expansion of the Asia Pacific nucleic acid therapeutics market is also being aided by the regulatory community’s rising support for developing nucleic acid therapies.
Nucleic Acid Therapeutics Market Strategic Developments
Nucleic Acid Therapeutics Market Competitive Landscape
The prominent market players in the global nucleic acid therapeutics market include:
The increased prevalence of chronic diseases and the high efficacy of nucleic acid therapeutics are fueling revenue growth in the global market.
Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Moderna Inc., and Stoke Therapeutics Inc. are among the top market players.
The high cost of products and stringent regulations are the most prominent restraints in the global nucleic acid therapeutics market.
Nucleic acid-based therapeutics are medications based on nucleic acid, mainly DNA and RNA. It is a new class of therapeutics touted for treating several rare diseases.
The global nucleic acid therapeutics market is expected to grow at a revenue CAGR of 11.55% during the forecast period from 2022 to 2030.
*Insights on financial performance are subject to the availability of the information in the public domain